| Title: |
Pre‐Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients |
| Authors: |
Li, Roger M.; Tan, Dino B. A.; Tedja, Chantalia; Cooper, Wendy A.; Jo, Helen E.; Grainge, Christopher; Glaspole, Ian N.; Goh, Nicole; Ellis, Samantha; Hopkins, Peter M. A.; Zappala, Christopher; Keir, Gregory J.; Reynolds, Paul N.; Chapman, Sally; Walters, E. Haydn; Knight, Darryl; Baltic, Svetlana; Chih, HuiJun; Corte, Tamera J.; Moodley, Yuben P. |
| Contributors: |
Lung Foundation Australia; Boehringer Ingelheim España; National Health and Medical Research Council |
| Source: |
Respirology ; volume 30, issue 6, page 504-514 ; ISSN 1323-7799 1440-1843 |
| Publisher Information: |
Wiley |
| Publication Year: |
2025 |
| Collection: |
Wiley Online Library (Open Access Articles via Crossref) |
| Description: |
Background and Objective Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a poor prognosis. Antifibrotics slow the decline of pulmonary function after 12‐months, but limited studies have examined the role of circulatory biomarkers in antifibrotic treated IPF patients. Methods Serum from 98 IPF participants, from the Australian Idiopathic Pulmonary Fibrosis Registry were collected at four time‐points over 1 year post‐antifibrotic treatment and analysed as two separate cohorts. Patients were stratified as progressive, if they experienced ≥ 10% decline in FVC or ≥ 15% decline in DLCO or were deceased within 1 year of treatment initiation: or otherwise as stable. Ten molecules of interest were measured by ELISAs in patient serum. Results Baseline MMP7 levels were higher in progressive than stable patients in Cohort 1 ( p = 0.02) and Cohort 2 ( p = 0.0002). Baseline MMP7 levels also best differentiated progressive from stable patients (Cohort 1, AUC = 0.74, p = 0.02; Cohort 2, AUC = 0.81, p = 0.0003). Regression analysis of the combined cohort showed that elevated MMP7 levels predicted 12‐month progression (OR = 1.530, p = 0.010) and increased risk of overall mortality (HR = 1.268, p = 0.002). LASSO regression identified a multi‐biomarker panel (MMP7, ICAM‐1, CHI3L1, CA125) that differentiated progression more accurately than MMP7 alone. Furthermore, GAP combined with MMP7, ICAM‐1, CCL18 and SP‐D was more predictive of 3‐year mortality than GAP alone. Conclusion MMP7 along with a multi‐biomarker and GAP panel can predict IPF progression and mortality, with the potential for optimising management. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1111/resp.14894 |
| Availability: |
https://doi.org/10.1111/resp.14894; https://onlinelibrary.wiley.com/doi/pdf/10.1111/resp.14894 |
| Rights: |
http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.89ADB53B |
| Database: |
BASE |